Skip to main content
Contacts
Locations and phones

Call center 93 253 21 00

Monday to Sunday, from 8 am to 8:30 pm

Scheduling or change of appointment +34 93 253 21 00

Monday to Friday, from 8 am to 7 pm

Private Care - International Patients +34 93 600 97 83

Monday to Friday, from 8 am to 7 pm

SJD Barcelona Children's Hospital

Passeig Sant Joan de Déu, 2, 08950 Esplugues de Llobregat

How to arrive

Language -

Brain and spinal cord tumours are the most common solid tumours in the child population. The prognosis varies widely depending on the type of tumour.

Treatment

At SJD Barcelona Children's Hospital, we apply treatments in accordance with the most advanced chemotherapy and radiotherapy strategies.

Our unit specialised in Neuro-Oncology is composed of professionals from different specialities — oncologists, neurosurgeons, neurologists, neuropathologists, neurobiologists and neuroradiologists — who jointly decide upon the best management for each patient with a brain tumour.

We have developed a unique treatment for patients with spinal gliomas.

We are one of the few centres in Europe that biopsies brainstem tumours to further knowledge of this incurable cancer.

Why SJD Barcelona Children's Hospital?

A national reference centre

The SJD Barcelona Children's Hospital's Oncology and Haematology Department is the national reference centre of for the treatment of developmental cancer and an international reference centre for determined types of tumours.

Specialties and servicies

Research to fight diffuse brain stem tumours (DIPG)

Andrés Morales, tell us about the research of this tumour
https://www.youtube.com/watch?v=6J0vYSewxVo

Research

We have developed an animal model for diffuse intrinsic pontine glioma (DIPG) and established patient cell lines, which have allowed us to generate an antigenic product with which to develop vaccines.

DIPG is one of the few paediatric tumours for which there is no curative treatment today. That is why we have started the first clinical trial in the world with vaccines with autologous dendritic cells for DIPG patients.